hydromorphone has been researched along with Cardiovascular Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amirnovin, R; Koh, JY; Lieu, P; Nelson, LP; Okuhara, C; Rodgers, JW; Sanchez-Pinto, LN | 1 |
Bansal, M; Happich, M; Klein, R; Wielage, R; Wilson, K | 1 |
1 review(s) available for hydromorphone and Cardiovascular Diseases
Article | Year |
---|---|
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Gastrointestinal Diseases; Humans; Hydromorphone; Low Back Pain; Markov Chains; Middle Aged; Models, Economic; Naproxen; Ontario; Osteoarthritis; Outcome Assessment, Health Care; Oxycodone; Pregabalin; Pyrazoles; Quality-Adjusted Life Years; Quebec; Sulfonamides; Thiophenes | 2013 |
1 other study(ies) available for hydromorphone and Cardiovascular Diseases
Article | Year |
---|---|
Implementation of a Risk-Stratified Opioid and Benzodiazepine Weaning Protocol in a Pediatric Cardiac ICU.
Topics: Analgesics, Opioid; Benzodiazepines; Cardiovascular Diseases; Female; Humans; Hydromorphone; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Length of Stay; Lorazepam; Male; Methadone; Prospective Studies; Risk Assessment; Severity of Illness Index; Substance Withdrawal Syndrome | 2018 |